763P Re-VOLVE: Phase II trial in women with ovarian cancer progressing post-PARP-inhibitor with treatment adapted to real-time assessment of evolving genomic resistance. - Soberanis Pina, P.D.; Oza, A.M.; Dhani, N.; Wang, L.; Grant, R.; Garg, V.; Lee, J-S.; Benito, C.; Selim, F.R.; Arora, S.; Ramsahai, J.; Quintos, J.; et al. (Annals of Oncology, 2024)